Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STIM trial of ovarian stimulation with tamoxifen or letrozole in women with breast cancer
NL-OMON21429Active, not recruiting
- Sponsor
- Amsterdam UMC
- Start
- Aug 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of tamoxifen, letrozole and follicle-stimulating hormone in breast cancer (3 arms), sponsored by Amsterdam UMC. Primary endpoint: Number of oocytes retrieved at follicle aspiration. Started Aug 2013; status: active, not recruiting.
02
Drugs
tamoxifenletrozolefollicle-stimulating hormone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON21429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21429.